Market Place
Sourcing Support
Navidea Extends Reverse Stock Split Authority
21 May 2025 //
BUSINESSWIRE
Navidea Biopharmaceuticals extends plan to protect tax assets
31 Mar 2025 //
BUSINESSWIRE
Navidea Announces Results of Exploratory Analysis Completed on July 2, 2024
03 Jul 2024 //
BUSINESSWIRE
Navidea Biopharmaceuticals Schedules Special Stockholders Meeting For July 8
20 Jun 2024 //
BUSINESSWIRE
Navidea Bio Files Form 15 to Voluntarily Suspend its SEC Reporting Obligations
26 Jan 2024 //
BUSINESSWIRE
Navidea and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement
01 Dec 2023 //
BUSINESSWIRE
Navidea Bio Announces NYSE American’s Decision to Suspend Trading
05 Oct 2023 //
BUSINESSWIRE
Navidea Biopharmaceuticals NAVB Requests Oral Hearing With NYSE Hearing Panel
10 Aug 2023 //
BUSINESSWIRE
Navidea Announces NYSE American Has Commenced Delisting Proceedings
31 Jul 2023 //
BUSINESSWIRE
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
31 Jul 2023 //
BUSINESSWIRE
Navidea Bio Announces NYSE American Has Commenced Delisting Proceedings
28 Jul 2023 //
BUSINESSWIRE
Navidea Biopharma Hires Craig A. Dais, CPA as Chief Financial Officer
27 Jul 2023 //
BUSINESSWIRE
Navidea Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
13 Jul 2023 //
BUSINESSWIRE
Navidea Biopharma Rejects Unsolicited Offer To Acquire Certain Assets
30 Jun 2023 //
BUSINESSWIRE
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health
16 Jun 2023 //
BUSINESSWIRE
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results
07 Jun 2023 //
BUSINESSWIRE
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
02 Jun 2023 //
BUSINESSWIRE
Navidea Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors
01 Jun 2023 //
BUSINESSWIRE
Navidea Investors Purchase $1.1 Million in Preferred Shares at Market
22 May 2023 //
BUSINESSWIRE
Navidea Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
11 May 2023 //
BUSINESSWIRE
Navidea Biopharma Announces Intent to sell Cardinal Milestone Payment for $8 M
27 Apr 2023 //
BUSINESSWIRE
Navidea Enters Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
13 Apr 2023 //
BUSINESSWIRE
Navidea Hires G2G Ventures as Executive Consultants; CMO Steps Down
30 Mar 2023 //
BUSINESSWIRE
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
21 Mar 2023 //
BUSINESSWIRE
Navidea to Host Fourth Quarter 2022 Earnings Conference Call and Business Update
15 Mar 2023 //
BUSINESSWIRE
Navidea Announces the Notice of Allowance for U.S. Patent Application
03 Jan 2023 //
BUSINESSWIRE
Navidea Biopharmaceuticals Files Appeal in CRG Case
30 Nov 2022 //
BUSINESSWIRE
Navidea Announces 50th Participant Enrolled in PIII Trial in Arthritis
28 Nov 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Navidea Announces Details of Presentation at Immunotherapy Annual Meeting
07 Nov 2022 //
BUSINESSWIRE
Navidea to Host Third Quarter 2022 Earnings Conference Call and Business Update
04 Nov 2022 //
BUSINESSWIRE
Navidea Announces Acceptance of Abstract for Presentation at SITC
05 Oct 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors
30 Sep 2022 //
BUSINESSWIRE
Navidea Announces Results from its Two Phase 2B trials in Rheumatoid Arthritis
15 Sep 2022 //
BUSINESSWIRE
Navidea Announces Oral Ruling in Case Involving Attorney’s Fees
01 Sep 2022 //
BUSINESSWIRE
Navidea Announces Opening of Sites in Pivotal PIII Trial in Rheumatoid Arthritis
01 Sep 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and 2Q
30 Aug 2022 //
BUSINESSWIRE
Navidea Announces Subscriptions of Approx $14.2 Million from its Rights Offering
25 Aug 2022 //
BUSINESSWIRE
Navidea Announces Extension of Subscription Period to August 24, 2022
18 Aug 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
BUSINESSWIRE
Navidea Bio Announces Commencement of Rights Offering Subscription Period
04 Aug 2022 //
BUSINESSWIRE
Navidea Biopharma Announces Publication of Use of Tc99m Tilmanocept
01 Aug 2022 //
BUSINESSWIRE
Navidea Biopharma Announces Publication of Study Examining Tc99m Tilmanocept
25 Jul 2022 //
BUSINESSWIRE
Navidea Biopharma Informs Stockholders of Key Dates and Terms
20 Jul 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Announces Additional Bridge Loan Funding
05 Jul 2022 //
BUSINESSWIRE
Navidea Biopharma Accepts Abstract for Presentation at the SNMMI
24 May 2022 //
BUSINESSWIRE
Navidea Biopharma Announces Acceptance of Abstract for Presentation
23 May 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Navidea Biopharma to Host Q1 2022 Earnings Conference Call and Business Update
05 May 2022 //
BUSINESSWIRE
Navidea Biopharma Updates Third-Party Asset Valuation of Tc99m
20 Apr 2022 //
BUSINESSWIRE
Navidea Biopharma Announces Positive Prelim Results on Ongoing Phase 2B Study
20 Apr 2022 //
BUSINESSWIRE
Navidea Biopharma Announces the Notice of Allowance for U.S. Patent Application
19 Apr 2022 //
BUSINESSWIRE
Navidea Biopharma Announces the Regulatory Approval of Lymphoaim in India
18 Apr 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
12 Apr 2022 //
BUSINESSWIRE
Navidea Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets
12 Apr 2022 //
BUSINESSWIRE
Navidea Bio Announces New Sr. Regulatory Consultant; Return of Former Director
07 Apr 2022 //
BUSINESSWIRE
Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
23 Mar 2022 //
BUSINESSWIRE
Navidea BioPharma to Host Q4 2021 Earnings Conference Call and Business Update
16 Mar 2022 //
BUSINESSWIRE
Navidea Announces Research Agreement with University of Pennsylvania
07 Feb 2022 //
BUSINESSWIRE
Navidea`s Settlement of Platinum Litigation; Receipt of Noncompliance Notice
03 Feb 2022 //
BUSINESSWIRE
